Evidence map›Paper›PMID 19193989›Full record

ArticleActa crystallographica. Section F, Structural biology and crystallization communications2009

Structure of the ligand-binding domain of the EphB2 receptor at 2 A resolution.

Yehuda Goldgur, Sari Paavilainen, Dimitar Nikolov, J P Himanen

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Acta crystallographica. Section F, Structural biology and crystallization communications, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Yehuda GoldgurStructural Biology Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10065, USA.
Sari Paavilainen
Dimitar Nikolov
J P Himanen
Memorial Sloan Kettering Cancer Center · USUniversity of Turku · FI

Funding

STRUCTURAL STUDY OF EPH RECEPTORS AND EPHRINSR01NS038486 · NINDS · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI NIKOLOV, DIMITAR B · 1999 to 2018
$5.9M
Expression and structural study of Eph receptor kin(RMI)R21GM075886 · NIGMS · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI HIMANEN, JUHA P · 2005 to 2006
$474k
NIGMS NIH HHS GM75886NIGMS NIH HHS R21 GM075886NINDS NIH HHS NS38486NINDS NIH HHS R01 NS038486
6 · The paper itself

Abstract

Eph tyrosine kinase receptors, the largest group of receptor tyrosine kinases, and their ephrin ligands are important mediators of cell-cell communication regulating cell attachment, shape and mobility. Recently, several Eph receptors and ephrins have also been found to play important roles in the progression of cancer. Structural and biophysical studies have established detailed information on the binding and recognition of Eph receptors and ephrins. The initial high-affinity binding of Eph receptors to ephrin occurs through the penetration of an extended G-H loop of the ligand into a hydrophobic channel on the surface of the receptor. Consequently, the G-H loop-binding channel of Eph receptors is the main target in the search for Eph antagonists that could be used in the development of anticancer drugs and several peptides have been shown to specifically bind Eph receptors and compete with the cognate ephrin ligands. However, the molecular details of the conformational changes upon Eph/ephrin binding have remained speculative, since two of the loops were unstructured in the original model of the free EphB2 structure and their conformational changes upon ligand binding could consequently not be analyzed in detail. In this study, the X-ray structure of unbound EphB2 is reported at a considerably higher 2 A resolution, the conformational changes that the important receptor loops undergo upon ligand binding are described and the consequences that these findings have for the development of Eph antagonists are discussed.

Indexed as

AnimalsCrystallography, X-RayLigandsMiceProtein BindingProtein Structure, SecondaryProtein Structure, TertiaryReceptor, EphB2LigandsReceptor, EphB2

Identifiers

PMID19193989
PMCPMC2635866
OpenAlexW1993092352

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.